Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Alberta

$27,000.00

Advancing multiple myeloma treatment: Lipid nanoparticle-based chimeric antigen receptor (CAR)-natural killer (NK) therapy optimization

EF 2024-25

Résumé
Chimeric Antigen Receptor (CAR) therapy is a cancer treatment in which a patient's immune cells are modified with a CAR gene, a receptor that equips them to better destroy cancer cells. Traditionally, viruses are used to deliver the gene into patients' T immune cells. However, T cell therapy can cause toxic side effects, and using viruses may pose safety risks by triggering immune reactions. Additionally, CAR-T production is expensive and lengthy, which may delay timely treatment. Alternatively, natural killer (NK) immune cells offer the same powerful cancer-fighting ability while addressing CAR-T therapy risks. Unlike T cells, CAR-NK cells do not require a genetic match with each patient, meaning they can be manufactured from healthy donors and stored. This allows an off-the-shelf therapy that is faster, more cost-effective and accessible than CAR T-cell therapy.This project focuses on improving CAR-NK therapies for multiple myeloma (MM), the second most common blood cancer. Unlike traditional methods, we use lipid nanoparticles (LNPs) as a safer, more controlled way to deliver the CAR gene to NK cells. The CAR we will develop targets BCMA, a protein highly expressed on MM cells, making it an ideal therapeutic target. We will then introduce the anti-BCMA LNPs into NK cells from both patients and healthy donors. The modified CAR-NK cells will be tested for their ability to kill MM cancer cells in laboratory experiments, mouse models, and ultimately in clinical trials. By advancing CAR-NK therapies, this research aims to create safer, more effective, and readily available treatments for MM. This project will eventually establish an NK cell platform, swapping different CARs to target a wide range of cancers, paving the way for transformative cancer treatments.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
529628
Name
Hamie Angela
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Advancing multiple myeloma treatment: Lipid nanoparticle-based chimeric antigen receptor (CAR)-natural killer (NK) therapy optimization
Programtype2
Studentship Programs
Orgnameinp2
University of Alberta
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Adoptive Cell Therapy; Cancer Immunotherapy; Chimeric Antigen Receptor (Car) Immunotherapy; Gene Editing; Lipid Nanoparticles (Lnps); Mrna Therapeutics; Multiple Myeloma; Natural Killer (Nk) Cells; Non-Viral Delivery Systems; Off-The-Shelf Treatments
Abstract
Chimeric Antigen Receptor (CAR) therapy is a cancer treatment in which a patient's immune cells are modified with a CAR gene, a receptor that equips them to better destroy cancer cells. Traditionally, viruses are used to deliver the gene into patients' T immune cells. However, T cell therapy can cause toxic side effects, and using viruses may pose safety risks by triggering immune reactions. Additionally, CAR-T production is expensive and lengthy, which may delay timely treatment. Alternatively, natural killer (NK) immune cells offer the same powerful cancer-fighting ability while addressing CAR-T therapy risks. Unlike T cells, CAR-NK cells do not require a genetic match with each patient, meaning they can be manufactured from healthy donors and stored. This allows an off-the-shelf therapy that is faster, more cost-effective and accessible than CAR T-cell therapy.This project focuses on improving CAR-NK therapies for multiple myeloma (MM), the second most common blood cancer. Unlike traditional methods, we use lipid nanoparticles (LNPs) as a safer, more controlled way to deliver the CAR gene to NK cells. The CAR we will develop targets BCMA, a protein highly expressed on MM cells, making it an ideal therapeutic target. We will then introduce the anti-BCMA LNPs into NK cells from both patients and healthy donors. The modified CAR-NK cells will be tested for their ability to kill MM cancer cells in laboratory experiments, mouse models, and ultimately in clinical trials. By advancing CAR-NK therapies, this research aims to create safer, more effective, and readily available treatments for MM. This project will eventually establish an NK cell platform, swapping different CARs to target a wide range of cancers, paving the way for transformative cancer treatments.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Hamie, Angela
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~